ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 500M 1B 1.5B Q2 '21: 220.6M Q3 '21: 187.6M Q4 '21: 258.5M Q1 '22: 213.3M Q2 '22: 224.8M Q3 '22: 264.3M Q4 '22: 335M Q1 '23: 319.3M Q2 '23: 318.8M Q3 '23: 750.5M Q4 '23: 439.7M Q1 '24: 494.3M Q2 '24: 659.8M Q3 '24: 500.9M Q4 '24: 593.2M Q1 '25: 594.2M Q2 '25: 773.7M Q3 '25: 1.2B Q4 '25: 1.1B Q2 '26: 1.3B Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-300M -150M 0 150M 300M 450M Q2 '21: -146.2M Q3 '21: -181.7M Q4 '21: -194.6M Q1 '22: -146.7M Q2 '22: -191.7M Q3 '22: -258M Q4 '22: -188.6M Q1 '23: -149.8M Q2 '23: -229.8M Q3 '23: 213.9M Q4 '23: -116.4M Q1 '24: -43.4M Q2 '24: 48.6M Q3 '24: -76.9M Q4 '24: -105.2M Q1 '25: 18.1M Q2 '25: -16.2M Q3 '25: 368M Q4 '25: 131.7M Q2 '26: 231.4M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Net Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '21: -204.5M Q4 '21: -258.5M Q1 '22: -240.3M Q2 '22: -277.4M Q3 '22: -405.9M Q4 '22: -207.5M Q1 '23: -174.1M Q2 '23: -276M Q3 '23: 147.8M Q4 '23: -137.9M Q1 '24: -65.9M Q2 '24: -16.9M Q3 '24: -111.6M Q4 '24: -83.8M Q1 '25: -18.3M Q2 '25: -72.2M Q3 '25: 251.1M Q4 '25: 111.5M Q1 '26: 206M Q2 '26: 164.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 150M 300M 450M Q2 '21: 30.3M Q3 '21: 28.1M Q4 '21: 33.6M Q1 '22: 23.5M Q2 '22: 34M Q3 '22: 36.5M Q4 '22: 46.2M Q1 '23: 41.4M Q2 '23: 75.3M Q3 '23: 79.5M Q4 '23: 72M Q1 '24: 54.6M Q2 '24: 67.3M Q3 '24: 82M Q4 '24: 102.6M Q1 '25: 70.2M Q2 '25: 142M Q3 '25: 197.2M Q4 '25: 267.7M Q2 '26: 298.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-300M -150M 0 150M 300M 450M Q1 '21: -235.7M Q2 '21: -121.9M Q3 '21: -134M Q4 '21: -150.1M Q1 '22: -171.2M Q2 '22: -122.8M Q3 '22: -115.3M Q4 '22: -132M Q1 '23: -166.5M Q2 '23: -59M Q3 '23: 359.4M Q4 '23: -29.8M Q1 '24: -81.5M Q2 '24: 124.2M Q3 '24: 43.7M Q4 '24: -94.7M Q1 '25: -118.3M Q2 '25: 127.8M Q3 '25: 351M Q4 '25: 163.6M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Free Cash Flow Quarterly

-300M -150M 0 150M 300M 450M Q1 '21: -252.8M Q2 '21: -133.1M Q3 '21: -160.1M Q4 '21: -172M Q1 '22: -189.1M Q2 '22: -138.9M Q3 '22: -131.8M Q4 '22: -153.6M Q1 '23: -180.4M Q2 '23: -74.9M Q3 '23: 342.3M Q4 '23: -45.1M Q1 '24: -94.5M Q2 '24: 116.1M Q3 '24: 39.5M Q4 '24: -103.8M Q1 '25: -127.3M Q2 '25: 113.5M Q3 '25: 338.9M Q4 '25: 140.3M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 114.9M Q3 '20: 116M Q1 '21: 117.1M Q2 '21: 117.8M Q3 '21: 119.1M Q1 '22: 120.4M Q2 '22: 120.9M Q3 '22: 122.2M Q1 '23: 124.1M Q2 '23: 124.7M Q3 '23: 131.3M Q1 '24: 126.1M Q2 '24: 126.7M Q3 '24: 128.6M Q1 '25: 129.7M Q2 '25: 130.6M Q3 '25: 137.3M Q2 '26: 138.3M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q1 '20: -8.03 Q2 '20: -7.57 Q3 '20: -7.83 Q4 '20: -7.45 Q1 '21: -7.54 Q2 '21: -7.59 Q3 '21: -7.13 Q4 '21: -7.20 Q1 '22: -7.49 Q2 '22: -8.17 Q3 '22: -9.77 Q4 '22: -9.29 Q1 '23: -8.69 Q2 '23: -8.61 Q3 '23: -4.14 Q4 '23: -3.55 Q1 '24: -2.67 Q2 '24: -0.59 Q3 '24: -2.61 Q4 '24: -2.17 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.